Literature DB >> 21852700

High yield of colorectal neoplasia detected by colonoscopy following a positive faecal occult blood test in the NHS Bowel Cancer Screening Programme.

Thomas J W Lee1, Gayle M Clifford, Praveen Rajasekhar, Matthew D Rutter, Simon Kometa, Mary C Ritchie, Greg Waddup, David Nylander, Richard J Q McNally, Colin J Rees.   

Abstract

OBJECTIVES: The UK National Health Service Bowel Cancer Screening Programme (BCSP) is based on a strategy of biennial faecal occult blood (FOB) testing. Positive results are classified as 'abnormal' or 'weak positive' based on the number of positive windows per kit or need for repeat testing. Colonoscopy is offered to both groups. We evaluate the relationship between FOB test positivity and clinical outcome in the BCSP.
SETTING: The South of Tyne and Tees (UK) Bowel Cancer Screening Centres.
METHODS: Data were collected prospectively on all individuals who were offered FOB testing and colonoscopy between February 2007 and February 2009. Univariable and multivariable analyses were performed to investigate the relationship between FOB test positivity and clinical outcome.
RESULTS: Following FOB testing, 1524 individuals underwent colonoscopy, 1259 (83%) after a 'weak positive' and 265 (17%) an 'abnormal' result. Cancer was detected in 180 (11.8%) and adenomas in 758 (49.7%). Individuals with an 'abnormal' result were more likely to have cancer or be 'high risk' for the development of future adenomas (110/265, 41.5%) than those with 'weak positive' results, (236/1259, 18.7%, P < 0.0001). Those with Dukes stage B, C or D cancers or cancers proximal to the splenic flexure were more likely to have an 'abnormal' result.
CONCLUSIONS: The majority of colonoscopies were performed following 'weak positive' FOB results. Those with an 'abnormal' result were more likely to be diagnosed with cancer. The high yield of pathology in both the 'abnormal' and 'weak positive' groups justifies the need for colonoscopy in both.

Entities:  

Mesh:

Year:  2011        PMID: 21852700     DOI: 10.1258/jms.2011.011032

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  5 in total

1.  Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests.

Authors:  Richard F A Logan; Julietta Patnick; Claire Nickerson; Lynn Coleman; Matt D Rutter; Christian von Wagner
Journal:  Gut       Date:  2011-12-07       Impact factor: 23.059

2.  The impact of population-based faecal occult blood test screening on colorectal cancer mortality: a matched cohort study.

Authors:  G Libby; D H Brewster; P L McClements; F A Carey; R J Black; J Birrell; C G Fraser; R J C Steele
Journal:  Br J Cancer       Date:  2012-06-26       Impact factor: 7.640

Review 3.  The NHS Bowel Cancer Screening Program: current perspectives on strategies for improvement.

Authors:  Sara Koo; Laura Jane Neilson; Christian Von Wagner; Colin John Rees
Journal:  Risk Manag Healthc Policy       Date:  2017-12-04

4.  Optimising faecal occult blood screening:retrospective analysis of NHS Bowel Cancer Screening data to improve the screening algorithm.

Authors:  J Geraghty; P Butler; H Seaman; J Snowball; S Sarkar; R Blanks; S Halloran; K Bodger; C J Rees
Journal:  Br J Cancer       Date:  2014-09-16       Impact factor: 7.640

5.  Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity.

Authors:  Ni Ni Moe Myint; Ajay M Verma; Daniel Fernandez-Garcia; Panchali Sarmah; Patrick S Tarpey; Saif Sattar Al-Aqbi; Hong Cai; Ricky Trigg; Kevin West; Lynne M Howells; Anne Thomas; Karen Brown; David S Guttery; Baljit Singh; Howard J Pringle; Ultan McDermott; Jacqui A Shaw; Alessandro Rufini
Journal:  Cell Death Dis       Date:  2018-08-30       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.